Literature DB >> 33664234

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.

Maansi Joshi1, Joselle Cook1, Kristen McCullough1, Ahmad Nanaa1, Naseema Gangat1, James M Foran2, Hemant S Murthy2, Mohamed A Kharfan-Dabaja2, Lisa Sproat3, Jeanne Palmer3, Animesh Pardanani1, Ayalew Tefferi1, Kebede Begna1, Michelle Elliot1, Aref Al-Kali1, Mrinal Patnaik1, Mithun V Shah1, William J Hogan1, Mark R Litzow1, Hassan B Alkhateeb4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33664234      PMCID： PMC7933161          DOI： 10.1038/s41408-021-00437-z

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  12 in total

1.  Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Authors:  Ibrahim Aldoss; Jianying Zhang; Raju Pillai; Geoffrey Shouse; James F Sanchez; Matthew Mei; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Br J Haematol       Date:  2019-08-22       Impact factor: 6.998

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

3.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Authors:  Ibrahim Aldoss; Dongyun Yang; Ahmed Aribi; Haris Ali; Karamjeet Sandhu; Monzr M Al Malki; Matthew Mei; Amandeep Salhotra; Samer Khaled; Ryotaro Nakamura; David Snyder; Margaret O'Donnell; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

4.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

5.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

6.  Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

Authors:  Nelli Bejanyan; Daniel J Weisdorf; Brent R Logan; Hai-Lin Wang; Steven M Devine; Marcos de Lima; Donald W Bunjes; Mei-Jie Zhang
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-15       Impact factor: 5.742

Review 7.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

8.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

9.  Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Authors:  Ibrahim Aldoss; Dongyun Yang; Raju Pillai; James F Sanchez; Matthew Mei; Ahmed Aribi; Haris Ali; Karamjeet Sandhu; Monzr M Al Malki; Amandeep Salhotra; Samer Khaled; Weili Sun; Margaret O'Donnell; David Snyder; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Am J Hematol       Date:  2019-07-10       Impact factor: 10.047

10.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265
View more
  10 in total

1.  Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.

Authors:  Iman Abou Dalle; Ali Bazarbachi
Journal:  Bone Marrow Transplant       Date:  2021-08-10       Impact factor: 5.483

2.  Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.

Authors:  Jan Philipp Bewersdorf; Andriy Derkach; Lohith Gowda; Kamal Menghrajani; Susan DeWolf; Josel D Ruiz; Doris M Ponce; Brian C Shaffer; Roni Tamari; James W Young; Ann A Jakubowski; Boglarka Gyurkocza; Alexander Chan; Wenbin Xiao; Jacob Glass; Amber C King; Sheng F Cai; Anthony Daniyan; Christopher Famulare; Bernadette M Cuello; Nikolai A Podoltsev; Mikhail Roshal; Sergio Giralt; Miguel-Angel Perales; Stuart Seropian; Christina Cho; Amer M Zeidan; Thomas Prebet; Eytan M Stein; Martin S Tallman; Aaron D Goldberg; Maximilian Stahl
Journal:  Leuk Lymphoma       Date:  2021-09-03

Review 3.  Treatment of AML Relapse After Allo-HCT.

Authors:  Jonathan A Webster; Leo Luznik; Ivana Gojo
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 4.  Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Authors:  Serena Brancati; Lucia Gozzo; Giovanni Luca Romano; Calogero Vetro; Ilaria Dulcamare; Cinzia Maugeri; Marina Parisi; Laura Longo; Daniela Cristina Vitale; Francesco Di Raimondo; Filippo Drago
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

5.  Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.

Authors:  Cheng-Hsien Lin; Tsung-Chih Chen; Yu-Hsuan Shih; Cheng-Wei Chou; Chiann-Yi Hsu; Po-Hsien Li; Chieh-Lin Jerry Teng
Journal:  J Int Med Res       Date:  2022-02       Impact factor: 1.671

6.  A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).

Authors:  Silvia Park; Daehun Kwag; Tong Yoon Kim; Jong Hyuk Lee; Joon Yeop Lee; Gi June Min; Sung Soo Park; Seung-Ah Yahng; Young-Woo Jeon; Seung-Hwan Shin; Jae-Ho Yoon; Sung-Eun Lee; Byung Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Jong Wook Lee; Hee-Je Kim
Journal:  Ther Adv Hematol       Date:  2022-03-23

7.  Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.

Authors:  Carmine Liberatore; Maria Teresa Lupo Stanghellini; Francesca Lorentino; Luca Vago; Matteo Giovanni Carrabba; Raffaella Greco; Sarah Marktel; Andrea Assanelli; Francesca Farina; Consuelo Corti; Massimo Bernardi; Jacopo Peccatori; Katja Sockel; Jan Moritz Middeke; Johannes Schetelig; Anika Bergmann; Christina Rautenberg; Fabio Ciceri; Martin Bornhäuser; Thomas Schroeder; Friedrich Stölzel
Journal:  Ther Adv Hematol       Date:  2022-06-17

8.  Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany.

Authors:  Krischan Braitsch; Laura K Schmalbrock; Paul Jung; Irmgard Bumeder; Philipp Kiewe; Judith S Hecker; Mareike Verbeek; Jörg Westermann; Lars Bullinger; Ulrich Keller; Florian Bassermann; Jan Krönke; Katharina S Götze; Kathrin Rieger
Journal:  Hemasphere       Date:  2022-08-09

9.  Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.

Authors:  Maximilian Fleischmann; Sebastian Scholl; Jochen J Frietsch; Inken Hilgendorf; Karin Schrenk; Jakob Hammersen; Florian Prims; Christian Thiede; Andreas Hochhaus; Ulf Schnetzke
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-31       Impact factor: 4.322

Review 10.  The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation.

Authors:  Iman Abou Dalle; Ali Atoui; Ali Bazarbachi
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.